newsfilter
← Earnings
Earnings Releases·

Lantern Pharma — Third Quarter 2026 Earnings Summary

Lantern Pharma reported third-quarter 2026 financial results showing a net income of approximately $0.7 million, driven by a non-cash gain from warrant accounting, while operating expenses were impacted by a $2.0 million accrual for a proposed legal settlement. The company closed a registered direct offering in September 2026 for gross proceeds of $4.0 million, bringing its total cash, cash equivalents, and marketable securities to approximately $7.6 million. Clinically, the company engaged its first site for a Phase 1b/2 trial of LP-184 in triple-negative breast cancer, opened Part 2 of the HARMONIC trial for LP-300 in Taiwan, and published peer-reviewed Phase 1a data for LP-184 in glioblastoma. Leadership changes included the resignation of CEO Panna Sharma and the appointment of CFO David Margrave as Interim CEO, alongside the formation of a new subsidiary, Open Medicine AI, to commercialize its AI platform.

Company
LANTERN PHARMA INC
Sector
Healthcare
Industry
Biotechnology